Clinical Trial Update: Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects? [Phase 4]

View source ↗

Summary

Phase 4 update on low-dose acitretin (17.5 mg/day) for psoriasis, suggesting comparable efficacy with potentially fewer side effects.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Acitretin (Acitretin)

Snippet

Sponsor: Frankel, Amylynne, M.D. | Conditions: Psoriasis | Phase 4 | Status: UNKNOWN